Fuel-cell maker Plug Power Inc (NASDAQ:PLUG)’s net loss rose more than eight-fold in the first quarter, hurt by a $68.4 million charge related to its stock warrants. Plug Power Inc (NASDAQ:PLUG), weekly performance is -3.29%. On last trading day company shares ended up $3.82. Analysts mean target price for the company is $7.75. Plug Power Inc (NASDAQ:PLUG), distance from 50-day simple moving average (SMA50) is -39.15%.
MannKind Corporation (NASDAQ:MNKD), has developed a product called AFREZZA for the delivery of insulin in Type 1 and Type 2 diabetic patients. The simplistic description of AFREZZA is that it’s an insulin inhaler that could render insulin injections obsolete in the future. MannKind Corporation (NASDAQ:MNKD), advanced 6.53% in last trading session and ended the day on $7.01. MNKD, its return on assets is -78.70%. MannKind Corporation (NASDAQ:MNKD), quarterly performance is 24.51%.
On May 12, 2014, Gogo Inc (NASDAQ:GOGO), a leading aircraft communications service provider to the global aviation industry, announced its financial results for the quarter ended March 31, 2014. Gogo reported record first quarter revenue of $95.7 million, up 35% year-over-year. Adjusted EBITDA for Q1 2014 was $5.3 million, up 87% from $2.9 million in Q1 2013, driven by strong performance by our CA-NA and BA segments that was partially offset by an increased segment loss in our CA-ROW segment as we continued to invest in our international expansion. Net loss attributable to common stock for Q1 2014 was $16.9 million, or $0.20 per share, compared to net loss attributable to common stock of $32.5 million, or $4.77 per share, in Q1 2013. Gogo Inc (NASDAQ:GOGO), shares moved up 4.52% in last trading session and was closed at $13.42, while trading in range of $12.50 – 13.72. Gogo Inc (NASDAQ:GOGO), year to date (YTD) performance is -45.93%.
On May 12, 2014, Insys Therapeutics Inc (NASDAQ:INSY), issued a clarifying statement regarding its Subsys (fentanyl sublingual spray) product. Insys Therapeutics Inc (NASDAQ:INSY), ended the last trading day at $23.01. Company weekly volatility is calculated as 16.28% and price to cash ratio as 17.33. Insys Therapeutics Inc (NASDAQ:INSY), showed a negative weekly performance of 41.85%.
On May 13, 2014, Dendreon Corporation (NASDAQ:DNDN), has recently commenced sale of Provenge, its vaccine that can prevent prostrate cancer. This news has brought a lot of hope in the market. Dendreon Corporation (NASDAQ:DNDN), weekly performance is -10.37%. On last trading day company shares ended up $2.16. Analysts mean target price for the company is $2.77. Dendreon Corporation (NASDAQ:DNDN), distance from 50-day simple moving average (SMA50) is -21.57%.
Leave a Reply